Efficacy of Shenqi Pollen Capsules for High-Altitude Deacclimatization Syndrome via Suppression of the Reoxygenation Injury and Inflammatory Response
Efficacy of Shenqi Pollen Capsules for High-Altitude Deacclimatization Syndrome via Suppression of the Reoxygenation Injury and Inflammatory Response
复制标题
参芪花粉胶囊通过抑制复氧损伤和炎症反应治疗高原脱适应综合症的疗效
DOI：
10.1155/2019/4521231
复制
发表时间：
2019-11-15
影响因子：
4.1
通讯作者：
Wang, Guansong
中科院分区：
文献类型：
--
作者：
He, Binfeng;Hu, Mingdong;Wang, Guansong
高原脱适应综合征（HADAS）参与缺氧-复氧损伤和炎症反应，诱发一系列症状，已成为严重的公共卫生问题。在这里，我们在一项多中心、双盲、随机、安慰剂对照研究中，研究了使用参芪花粉胶囊（SPC）对 HADAS 受试者预防 HADAS 的机制和潜在方法。所有受试者在返回较低海拔之前都在同一高海拔（3650米）停留4-8个月。在研究的第三天，20 个集群中的受试者 (n = 288) 被诊断患有轻度或中度 HADAS。我们随机分配 20 组受试者 (1 : 1) 接受 SPC 或安慰剂治疗 7 周，然后随访至第 14 周。主要终点是受试者在 14 周随访期间记录的 HADAS 评分。与安慰剂相比，SPC 治疗显着降低了受试者的 HADAS 评分并降低了症状持续的发生率。 SPC 治疗还降低了 CK、CK-MB、LDH、IL-17A、TNF-α 和 miR-155 的血清水平，并升高了 IL-10 和 miR-21 水平。因此，我们证明 SPC 通过抑制缺氧-复氧损伤和炎症反应，有效改善这些受试者的 HADAS 症状。
High-altitude deacclimatization syndrome (HADAS) is involved in hypoxia-reoxygenation injury and inflammatory response, induced a series of symptoms, and has emerged as a severe public health issue. Here, we investigated the mechanism as well as potential means to prevent HADAS using Shenqi pollen capsules (SPCs) in subjects with HADAS in a multicenter, double-blinded, randomized, placebo-controlled study. All subjects were at the same high altitude (3650 m) for 4-8 months before returning to lower altitudes. Subjects (n = 288) in 20 clusters were diagnosed with mild or moderate HADAS on the third day of the study. We randomly allocated 20 clusters of subjects (1 : 1) to receive SPCs or a placebo for 7 weeks, and they were then followed up to the 14th week. The primary endpoints were subjects' HADAS scores recorded during the 14 weeks of follow-up. Compared with the placebo, SPC treatment significantly decreased the subjects' HADAS scores and reduced the incidence of symptom persistence. SPC therapy also reduced the serum levels of CK, CK-MB, LDH, IL-17A, TNF-α, and miR-155 and elevated IL-10 and miR-21 levels. We thus demonstrate that SPCs effectively ameliorated HADAS symptoms in these subjects via suppression of the hypoxia-reoxygenation injury and inflammatory response.